Navigation Links
Cancer risk found for long-term hormone therapy
Date:8/11/2010

Using postmenopausal hormone therapy for more than 15 years increases a woman's risk of developing breast cancer, particularly among leaner women according to research at the Keck School of Medicine of the University of Southern California (USC).

An analysis of the California Teachers Study focused on postmenopausal hormone therapy use among more than 55,000 women for nearly 10 years. The research was conducted by a team including first author Tanmai Saxena, an M.D. Ph.D student at the Keck School. The research was published today in Cancer Epidemiology, Biomarkers and Prevention, an American Association for Cancer Research journal.

Compared with women who never used postmenopausal hormone therapy, women who used estrogen therapy for more than 15 years were at a 19 percent increased risk of breast cancer. The risk was even more pronounced for women who used combined therapy with estrogen plus progestin for 15 or more years. These women had an increased risk of 83 percent, Saxena said.

"This study shows that there needs to be a personalized conversation with women about the risks of using postmenopausal hormone therapy," said Saxena. "Different women appear to have different risks from hormones."

Thinner women who go on hormone therapy also appear to be at higher risk, Saxena said.

The research revealed that body mass index (BMI) may be an indicator of breast cancer risk for women who use postmenopausal hormone therapy. Women with a BMI of 30 or less appear to be at increased risk of breast cancer from combined therapy, while women with a BMI of 30 or higher were at less risk. Women with a BMI of 25 or less were at the highest risk.

The purpose of the study was to elaborate on the Women's Health Initiative findings regarding the effects of postmenopausal hormone therapy on breast cancer risk. The 15-year WHI, conducted by the National Institutes of Health, was halted in 2002 after increased risks of ca
'/>"/>

Contact: Leslie Ridgeway
leslie.ridgeway@usc.edu
323-442-2823
University of Southern California
Source:Eurekalert

Page: 1 2

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... and POINT ROBERTS, Washington , ... source covering leading sectors including technology and tech stocks, releases ... marketplace featuring master pickpocket and security consultant Apollo Robbins ... stolen and talks about the Wocket™ biometric smart wallet, a ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch in December ... people to eliminate the pain of trying to remember their ... own biometrics fused to their smartphones. To assist people who ... , the company that created 1U and focuses on redefining ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... New research offers tantalizing clues as to why some ... kill themselves. The research is published in the ... Psychological Association (APA). , Neuroscientists at the University of ... doses of fluoxetine hydrochloride, which is sold in the ...
... remarkable fossils found in New Zealand will prompt a major rewrite ... "land of birds" was once home to mammals as well. , ... leg - belonged to a unique, mouse-sized land animal unlike any ... fossil bed, in the Central Otago region of South Island. ...
... during cell division, first described in the late 1800s ... in biology classes, has long fascinated biologists. However, ... division, the "chromosome-spindle" connection, which is critical for the ... elusive. , Researchers at the University of ...
Cached Biology News:Adolescent but not adult hamsters are more aggressive on low dose of fluoxetine 2Tiny bones rewrite textbooks 2Two central mysteries in genome inheritance solved at UCSD 2Two central mysteries in genome inheritance solved at UCSD 3
(Date:2/26/2015)... -- S&P Capital IQ (MHFI) announced today that it ... Therapeutics Holdings Inc . MabVax Therapeutics ... focused on the development of vaccine and antibody-based therapies ... cancer. MabVax has discovered a pipeline of human monoclonal ... by patients who have been immunized against targeted cancers. ...
(Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
(Date:2/26/2015)... Feb. 26, 2015 BioEnterprise today announced that ... attracted more than $2 billion in growth funding during ... national investors, strategic sources, state – including the Ohio ... the $2 billion has been raised in the past ... the heels of the BioEnterprise Midwest Healthcare Growth ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... from $31.0 million in Q1,08 , - Home Market: $14.4 ... Gross Margin: 21%, up from 13% in Q1,08 , - ... 8 NxStage Medical, Inc. (Nasdaq: NXTM ), ... revenue for the first quarter of 2009 of $33.7 million, ...
... DIEGO, May 7 Cadence Pharmaceuticals, Inc. (Nasdaq: ... on in-licensing, developing and commercializing proprietary product candidates ... reported financial results for the first quarter ended ... development program for Acetavance(TM), our proprietary formulation of ...
... May 7 Encorium Group, Inc. ... contract research organization (CRO) that provides design, development, ... registries to many of the world,s leading pharmaceutical ... Ph.D. has been appointed Head Consultant of Encorium,s ...
Cached Biology Technology:NxStage Reports First Quarter 2009 Financial Results 2NxStage Reports First Quarter 2009 Financial Results 3NxStage Reports First Quarter 2009 Financial Results 4NxStage Reports First Quarter 2009 Financial Results 5NxStage Reports First Quarter 2009 Financial Results 6NxStage Reports First Quarter 2009 Financial Results 7NxStage Reports First Quarter 2009 Financial Results 8NxStage Reports First Quarter 2009 Financial Results 9NxStage Reports First Quarter 2009 Financial Results 10NxStage Reports First Quarter 2009 Financial Results 11Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 2Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 3Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 4Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 5Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 6Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 7Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 2Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 3Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 4